Forschungs- & Entwicklungsinformationsdienst der Gemeinschaft - CORDIS

ERC

FUTUREGENES Berichtzusammenfassung

Project ID: 250050
Gefördert unter: FP7-IDEAS-ERC
Land: Finland

Final Report Summary - FUTUREGENES (Gene transfer techniques in the treatment of cardiovascular diseases and malignant glioma)

FutureGenes project developed a new, novel site-specifically integrating gene transfer vector which targeted a new, safe location in human genome and will provide an entirely new tool to achieve safe, long-lasting gene transfer effects. New VEGFs and designer VEGFs developed and tested in the FutureGenes project were very efficient in treating severe ischemic conditions and can be delivered in a targeted fashion in the myocardium using a precision catheter system using our adenoviral gene transfer vectors. Safety of the treatments has also shown to be very good in both mice and pigs. In the course of these studies we also developed a new chronic cardiac ischemia model based on bottle-neck stents which will greatly enhance the predictive value of translational research in ischemic conditions. In addition, several clinically relevant imaging methods, such as photoacustic imaging, PET and novel MRI methods were successfully applied in the new chronic ischemia model. Finally, in the FutureGenes project we conducted a clinical trial in chronic ischemia of 30 patients where a new member of the VEGF family, VEGF-DdNdC, was delivered in the myocardium using the precision catheter system. The trial was finished within the grant period as planned, and showed that increased blood flow can be achieved in the ischemic myocardium three months after the therapy. Safety of the treatment was also excellent. Thus, the successful clinical trial in the FutureGenes project in ischemic heart disease shows that local gene transfer methods have great potential to treat also chronic acquired diseases, such as coronary heart disease.

Kontakt

Jaana Backman, (Head of the Research Service Manager)
Tel.: +358 50 5554446
Fax: +358 17 162187
E-Mail-Adresse
Datensatznummer: 183307 / Zuletzt geändert am: 2016-05-26
Informationsquelle: SESAM